951403-91-1Relevant academic research and scientific papers
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-l
Devasthale, Pratik V.,Chen, Sean,Jeon, Yoon,Qu, Fucheng,Shao, Chunning,Wang, Wei,Zhang, Hao,Cap, Michael,Farrelly, Dennis,Golla, Rajasree,Grover, Gary,Harrity, Thomas,Ma, Zhengping,Moore, Lisa,Ren, Jimmy,Seethala, Ramakrishna,Cheng, Lin,Sleph, Paul,Sun, Wei,Tieman, Aaron,Wetterau, John R.,Doweyko, Arthur,Chandrasena, Gamini,Chang, Shu Y.,Humphreys, W. Griffith,Sasseville, Vito G.,Biller, Scott A.,Ryono, Denis E.,Selan, Fred,Hariharan, Narayanan,Cheng, Peter T. W.
, p. 2248 - 2250 (2005)
Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR α/γ dual agonist that shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ (EC50 = 110 nM). Compound 2 shows excellent efficacy for lo
PROCESS OF PREPARING SUBSTITUTED CARBAMATES AND INTERMEDIATES THEREOF
-
Page/Page column 14-15, (2008/06/13)
An improved process of preparing substituted carbamate derivatives, and crystalline forms thereof, useful for the treatment of dyslipidemia and diabetes, and intermediates thereof are provided.
